for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QIA.DE

Latest Trade

30.60EUR

Change

-0.12(-0.39%)

Volume

1,096,581

Today's Range

30.43

 - 

30.75

52 Week Range

29.01

 - 

37.03

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
30.72
Open
30.74
Volume
1,096,581
3M AVG Volume
8.40
Today's High
30.75
Today's Low
30.43
52 Week High
37.03
52 Week Low
29.01
Shares Out (MIL)
226.97
Market Cap (MIL)
7,054.59
Forward P/E
23.93
Dividend (Yield %)
--

Next Event

Qiagen NV at Berenberg and Goldman Sachs German Corporate Conference

Latest Developments

More

Qiagen Announces Change In Global Sales Structure

Qiagen Affirms Q2 Results

Qiagen Says Total Net Sales Rose 1% To $381.6 Mln In Q2 Of 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry

Biotechnology & Drugs

Contact Info

Hulsterweg 82

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Hakan Bjorklund

Independent Chairman of the Supervisory Board

Peer M. Schatz

Managing Director, Chief Executive Officer, Member of the Executive Committee

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Barthold Piening

Senior Vice President, Head of Global Operations, Member of the Executive Committee

Annette Koch

Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee

Key Stats

2.71 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.3K

2017

1.4K

2018

1.5K

2019(E)

1.6K
EPS (USD)

2016

1.110

2017

1.270

2018

1.340

2019(E)

1.408
Price To Earnings (TTM)
42.09
Price To Sales (TTM)
5.16
Price To Book (MRQ)
2.94
Price To Cash Flow (TTM)
19.41
Total Debt To Equity (MRQ)
67.10
LT Debt To Equity (MRQ)
53.63
Return on Investment (TTM)
4.28
Return on Equity (TTM)
3.56

Latest News

German stocks - Factors to watch on July 25

The following are some of the factors that may move German stocks on Thursday:

German stocks - Factors to watch on June 17

The following are some of the factors that may move German stocks on Monday:

BRIEF-FDA Approves Novartis' Piqray, the First Pi3k Inhibitor For Breast Cancer

* FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY Source text for Eikon: Further company coverage:

German stocks - Factors to watch on May 7

The following are some of the factors that may move German stocks on Tuesday:

German stocks - Factors to watch on May 6

The following are some of the factors that may move German stocks on Monday:

German stocks - Factors to watch on April 15

The following are some of the factors that may move German stocks on Monday:

German stocks - Factors to watch on April 4

The following are some of the factors that may move German stocks on Thursday:

Swiss stocks - Factors to watch on March 8

The Swiss blue-chip SMI was seen opening down percent 0.33 percent at 9,294 points on Friday, according to premarket indications by bank Julius Baer.

BRIEF-Qiagen And Tecan To Collaborate On Streamline Preanalytical Processing Of QuantiFERON-TB Gold Plus

* QIAGEN AND TECAN ANNOUNCE COLLABORATION TO STREAMLINE PREANALYTICAL PROCESSING OF QUANTIFERON-TB GOLD PLUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

German stocks - Factors to watch on Feb. 19

The following are some of the factors that may move German stocks on Tuesday:

German stocks - Factors to watch on Feb. 5

The following are some of the factors that may move German stocks on Tuesday:

German stocks - Factors to watch on Feb. 4

The following are some of the factors that may move German stocks on Monday:

German stocks - Factors to watch on Jan. 17

The following are some of the factors that may move German stocks on Thursday:

German stocks - Factors to watch on Jan. 15

The following are some of the factors that may move German stocks on Tuesday:

German stocks - Factors to watch on Dec. 7

The following are some of the factors that may move German stocks on Friday:

BRIEF-Qiagen Announces New Collaboration With Novartis

* QIAGEN ANNOUNCES NEW COLLABORATION TO DEVELOP COMPANION DIAGNOSTIC TO GUIDE TREATMENT FOR PATIENTS WITH PIK3CA-MUTATED ADVANCED BREAST CANCER

Drugmaker UCB backs Brexit Britain with 1 billion pound investment

Belgian drugmaker UCB <UCB.BR> expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty.

BRIEF-Blocktrade - Qiagen Bookrunner Says Deal Upsized To $500 Mln On Convertible Notes

* BLOCKTRADE - QIAGEN: BOOKRUNNER SAYS DEAL UPSIZED TO $500M; BOOKS TO CLOSE AT 13.30 UK Source text for Eikon: Further company coverage:

German stocks - Factors to watch on Oct. 30

The following are some of the factors that may move German stocks on Tuesday:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up